Skip to main content
Erschienen in: Journal of the International AIDS Society 4/2010

Open Access 01.11.2010 | Oral presentation

Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe

verfasst von: AS Walker, P Mugyenyi, P Munderi, J Hakim, AA Kekitiinwa, E Katabira, CF Gilks, C Kityo, P Nahirya-Ntege, K Nathoo, D Gibb

Erschienen in: Journal of the International AIDS Society | Sonderheft 4/2010

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Purpose of study

Adults initiating ART in low-income countries have higher mortality in the first 3 months on ART than those in high-income countries, with more similar mortality risks after 6 months. However, the specific pattern of changing mortality risk after ART has not been investigated. It is also not known whether children initiating ART are at the same high risk of early mortality as adults in resource-limited settings.

Methods

We used flexible parametric proportional hazards models to investigate how the risks of death vary over the first year on ART in adults (18+ years) from the DART trial and children (6 months-15 years) from the ARROW trial. We then estimated survival after ART initiation according to pre-ART CD4/CD4% and investigated the impact of age, sex and CD4/CD4% in multivariable models.

Results

Similar changes in early mortality were observed in both adults and children. At all CD4/CD4%, mortality risk increased from enrolment to a maximum between days 30-45, then declined rapidly to day 180, then declining more slowly throughout the rest of the first year on ART. Estimated mortality 14, 30, 90, 180 and 365 days after ART initiation is shown in Table 1
Table 1
 
DART
DART
DART
DART
ARROW
ARROW
ARROW
ARROW
ARROW
ARROW
Age (years)
18+
18+
18+
18+
4-15
4-15
4-15
0-3
0-3
0-3
pre-ART CD4/CD4%
0-49
50-99
100-149
150-199
0-49
50-99
100+
0-4%
5-9%
10%+
N
1106
784
759
661
131
56
552
27
87
348
Deaths in 1st year
103
36
23
17
14
2
7
2
4
9
Days after ART
   
Estimated
cumulative
mortality
    
14
0.4%
0.1%
0.1%
0.1%
0.5%
0.1%
0.0%
0.4%
0.1%
0.1%
30
1.5%
0.6%
0.3%
0.3%
1.7%
0.5%
0.1%
1.5%
0.6%
0.3%
90
4.9%
2.1%
1.4%
1.1%
5.9%
2.3%
0.6%
5.2%
2.4%
1.3%
180
7.2%
3.4%
2.3%
1.8%
8.3%
3.5%
1.0%
7.4%
3.6%
2.0%
365
9.4%
4.5%
3.2%
2.5%
10.1%
4.5%
1.3%
9.1%
4.6%
2.6%
Pooling data across adults and children, after adjusting for CD4/CD4% group there was no evidence of an impact of age (p=0.29) or sex (p=0.17) on mortality during the first year on ART. There was also no evidence of a difference in mortality risk between those 4+ years with CD4<50 cells/mm3 and 0-3 with CD4%<5% (p=0.68), those 4+ years with CD4 50-99 and 0-3 with CD4% 5-<10% (p=0.48) or those 4+ years with CD4 100+ and 0-3 with CD4% 10%+ (p=0.24).

Conclusions

Children do not have significantly poorer survival on ART than adults. However, children aged 4 years and over and adults with low CD4 have remarkably similar, and high, risks of mortality in the first 3 months after ART initiation compared to those with higher CD4. Children under 4 years with low CD4% are also at similar higher mortality risks.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​2.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Metadaten
Titel
Early mortality following ART initiation in HIV-infected adults and children in Uganda and Zimbabwe
verfasst von
AS Walker
P Mugyenyi
P Munderi
J Hakim
AA Kekitiinwa
E Katabira
CF Gilks
C Kityo
P Nahirya-Ntege
K Nathoo
D Gibb
Publikationsdatum
01.11.2010
Verlag
BioMed Central
Erschienen in
Journal of the International AIDS Society / Ausgabe Sonderheft 4/2010
Elektronische ISSN: 1758-2652
DOI
https://doi.org/10.1186/1758-2652-13-S4-O37

Weitere Artikel der Sonderheft 4/2010

Journal of the International AIDS Society 4/2010 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.